The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Assessing patient-reported nutritional status and outcomes in SCLC
Bjorn Henning Gronberg, MD, PhD, Norwegian University of Science and Technology, Trondheim, Norway, discusses the nutritional status of patients with limited-stage small cell lung cancer (LS-SCLC), stating that poor nutritional status is not a contraindication to concurrent chemoradiotherapy, and that patients with poor nutritional status can still tolerate and benefit from standard treatment. Weight loss in itself does not appear to have a negative impact on prognosis, and that patients with a history of weight loss before diagnosis should also be offered concurrent chemoradiotherapy. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
